Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant

• Conditions: Kidney Transplant Infection; Liver Transplant Infection; Polyomavirus Infections; BK Viremia
• Interventions: Procedure: Simultaneous Liver-Kidney Transplant

• Registration Number: NCT05224583
• Lead Sponsor: Methodist Health System

Brief Summary

The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.

Detailed Description

The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%. Immunosuppression reduction is the management cornerstone for BKV and has been shown to be effective at clearing the virus while maintaining graft function in both kidney alone and simultaneous kidney-pancreas transplant recipients. However, there is a lack of published data on the prevalence and outcomes in simultaneous liver-kidney (SLK) transplant recipients.

Study Timeline

• Study Start: 2021-11-17
• Status Verified: 2022-02
• Study First Submitted: 2022-02-03
• Study First Submitted QC: 2022-02-03
• Study First Posted: 2022-02-04
• Last Update Submitted: 2022-02-21
• Last Update Posted: 2022-03-09
• Primary Completion: 2022-11-17
• Study Completion: 2022-11-17

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Age 18 years or older
• SLK recipients transplanted at MDMC between 2015-2020

Exclusion Criteria

• Below 18 years of age
• Patients who did not undergo SLK transplant at MDMC

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Simultaneous Liver-Kidney Transplant patients population at MDMC	Simultaneous Liver-Kidney Transplant	Consecutive SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).

Primary Outcome Measures

Name	Time	Method
To characterize the prevalence of BKV in the SLK patient population at MDMC.	over a 6-year period (2015 to 2020).	number of SLK transplant recipients who were transplanted at MDMC

Trial Locations

Locations (1)

Methodist Dallas Medical Center; 🇺🇸 Dallas, Texas, United States